{
    "clinical_study": {
        "@rank": "83924", 
        "acronym": "SOPRANo", 
        "arm_group": [
            {
                "arm_group_label": "Neuroendocrine Tumours", 
                "description": "The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations."
            }, 
            {
                "arm_group_label": "Acromegaly", 
                "description": "The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to identify predictive factors for the response to Lanreotide\n      treatment in Acromegaly as well as in Neuroendocrine Tumours."
        }, 
        "brief_title": "Somatuline Predictive Factors in Acromegaly and NET", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acromegaly", 
            "Neuroendocrine Tumours"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acromegaly", 
                "Neuroendocrine Tumors"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent (also mandatory in case of retrospective documentation of\n             subject data)\n\n          -  Diagnosis of acromegaly or NET with the intention to be treated with ATG or already\n             on treatment with ATG\n\n        Exclusion Criteria:\n\n          -  The subject has already been included in this study\n\n          -  Participation in an interventional trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Clinics and private practitioners who treat acromegaly and/or NET subjects with Somatuline\n        Autogel\u00ae 60, 90 or 120 mg."
            }
        }, 
        "enrollment": {
            "#text": "152", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840449", 
            "org_study_id": "A-94-52030-240"
        }, 
        "intervention": {
            "arm_group_label": [
                "Neuroendocrine Tumours", 
                "Acromegaly"
            ], 
            "intervention_name": "Somatuline Autogel\u00ae 60, 90 or 120 mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Angiopeptin", 
                "Lanreotide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "University Hospital of Vienna"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20357"
                    }, 
                    "name": "ENDOC"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel\u00ae (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Philipp Hoffmanns, MD, PhD, MBA", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Austria: Agency for Health and Food Safety", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840449"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 2 years"
        }, 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}